NasdaqCM:COYABiotechs
Coya Therapeutics (COYA): Evaluating Valuation After Equity Raise and Milestone Progress in ALS Program
Coya Therapeutics has completed a $20 million follow-on equity offering. The company aims to strengthen its cash position and accelerate progress in the Phase 2 trial of COYA 302, its experimental ALS therapy. Investors are watching these milestones closely, as the FDA's recent acceptance of Coya's drug application and a triggered milestone payment bring new attention to the company’s clinical and financial strategy.
See our latest analysis for Coya Therapeutics.
After announcing the equity...